Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,520 Shares

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Trading Down 1.6 %

Shares of NYSE:GKOS opened at $101.97 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $5.77 billion, a price-to-earnings ratio of -35.53 and a beta of 0.99. Glaukos Co. has a 1-year low of $88.16 and a 1-year high of $163.71. The company has a 50 day moving average price of $130.52 and a 200 day moving average price of $135.64.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GKOS shares. Piper Sandler reissued an “overweight” rating and set a $180.00 target price (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus lifted their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. Finally, UBS Group started coverage on shares of Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $163.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after acquiring an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in Glaukos during the 4th quarter valued at $121,390,000. Alliancebernstein L.P. lifted its holdings in shares of Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier’s stock valued at $122,374,000 after purchasing an additional 755,035 shares in the last quarter. Norges Bank acquired a new stake in shares of Glaukos in the fourth quarter worth $84,490,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after buying an additional 207,338 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.